FDA seeks support for reorganization of cancer programs, but debate continues.
In a letter, ASCO reaffirms its views on oncology consolidation at FDA.
Also in this 8-page issue: NCI advisors approve $15-million set-aside for laboratory testing on “reduced harm” tobacco products.
Board approves continuation of partnerships between minority institutions and cancer centers for research, training, and outreach.
Duke recruits Judd Moul as chief of urology.
Foundation offers funds for mesothelioma research.
Other NCI funding opportunities listed.
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- ASCO & The Conquer Cancer Foundation announce merit awards
- CBER Director Vinay Prasad dared to “say no to drugs”
- By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”









